Cambridge Healthtech Institute’s 9th Annual

Preclinical Strategies, Models and Tools in Oncology

Translational Strategies, Novel Therapeutics and Tumor Models 

September 17-18, 2020

The rise of cancer immunotherapy instigated unique preclinical and translational challenges. In addition to immuno-oncology advances, we are witnessing a new wave of targeted and novel therapies that enrich the arsenal of combination cancer therapies. The demand for predictive and robust preclinical models and approaches to minimize translational failures in oncology and immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions adds to the complexity of translational research in oncology and immuno-oncology. Cambridge Healthtech Institute’s 9th Annual Preclinical Strategies, Models and Tools in Oncology conference is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Preliminary Agenda

Recommended Short Course*

SC6: In vitro and in vivo Modeling for Cancer Research - Detailed Agenda

*Separate registration required.

Translational Approaches and Novel Therapeutics 

Exploring Novel Immunotherapy Combinations to Overcome Resistance to PD-1 Blockade

Russell Jenkins, MD, PhD, Assistant Professor, Medicine, Center for Cancer Research, Massachusetts General Hospital

In vivo Imaging Techniques for Model Characterization and Guiding Combination Strategies

Tapan Nayak, PhD, Director, Translational Imaging Biomarkers, Merck & Co., Inc.

TGFβ-Blockade Uncovers Stromal Plasticity in Tumors by Revealing the Existence of a Novel Subset of Interferon-Licensed Fibroblasts

Viviana Cremasco, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis

Development of a T-Cell Redirecting CD3 Bispecific Antibody for the Treatment of Gastrointestinal Tumors

Lindsay King, PhD, Associate Research Fellow, Biomedicines Design, Pfizer


Friends & Enemies: Spatial Mapping of Regulatory T Lymphocytes in Inflammatory Microenvironments

Shawn O’Neill, DVM, PhD, Senior Director, Global Pathology & Investigative Toxicology, Global Microscopic Imaging Lead, Drug Safety Research & Development, Pfizer Worldwide Research & Development

Targeting Tumor-Promoting Inflammation via the Inflammasome Pathway – Lessons Learned

Pushpa Jayaraman, PhD, Senior Investigator I, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

New Modalities

Targeting Immune Checkpoint TIM-3 for Cancer Immunotherapy

Xiaomo Jiang, PhD, Principal Scientist II, Immuno-Oncology, Novartis Institutes for BioMedical Research

Novel Fully Synthetic Bicyclic Peptides as Tumor Targeted Immune Cell Modulators

Sailaja Battula, PhD, Associate Director, Immuno-Oncology, Bicycle Therapeutics

‘Smart’ Release Therapeutics Target Multi-Drug Resistance in Solid Cancers

Aaron Goldman, PhD, Faculty and Principal Investigator, Goldman Laboratory Drug Resistance Group, Harvard Medical School


Is There a Key Node in the TME to Tip the Balance?

Zhao Chen, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, Inc.

Transplanted Syngeneic Metastasis Models for Preclinical Applications

Viswanathan Muthusamy, PhD, Research Scientist; Executive Director, Center for Precision Cancer Modeling, Yale School of Medicine

Using Humanized Mouse Models to Evaluate IO Therapeutics

Virna Cortez-Retamozo, PhD, Lab Head, Senior Principal Scientist, Oncology-Pharmacology, Sanofi

For more details on the conference, please contact:
Marina Filshtinsky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5496

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286